Novartis Bioventures Ltd Insider Trading $AGLE Aeglea BioTherapeutics, Inc.
Get free email notifications about insider trading for Novartis Bioventures Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Novartis Bioventures Ltd. Novartis Bioventures Ltd is 10% Owner in Marina Biotech, Inc. ($MRNA) and 10% Owner in Altimmune, Inc. ($PIP) and 10% Owner in Tokai Pharmaceuticals Inc ($TKAI) and 10% Owner in AILERON THERAPEUTICS INC ($ALRN) and 10% Owner in Aerpio Pharmaceuticals, Inc. ($ZETAII) and 10% Owner in PROTEOSTASIS THERAPEUTICS, INC. ($PTI) and 10% Owner in Ra Pharmaceuticals, Inc. ($RARX) and 10% Owner in Akebia Therapeutics, Inc. ($AKBA) and in Galera Therapeutics, Inc. ($GRTX) and 10% Owner in Galera Therapeutics, Inc. ($GRTX) and in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in BICYCLE THERAPEUTICS plc ($BCYC).
Novartis Bioventures Ltd in Aeglea BioTherapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Novartis Bioventures Ltd:
Holdings: 2,175,314 shares
Current Value: $9,114,566
Latest Transaction: May 14 2018
$AGLE Market Capitalization: $56.54M
$AGLE Previous Close: $4.19
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Novartis Bioventures Ltd in Aeglea BioTherapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ATRX, AGLE, ARPO, ALRN, AKBA, ALT, BCYC, ELDN, GRTX, RARX, YMTX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.06 | 19,550 | 196,673 | 2,175,314 | 2.2 M to 2.2 M (-0.89 %) | |
| May 11 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.13 | 22,725 | 230,204 | 2,194,864 | 2.2 M to 2.2 M (-1.02 %) | |
| May 11 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.11 | 51,230 | 517,935 | 2,217,589 | 2.3 M to 2.2 M (-2.26 %) | |
| May 09 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.03 | 26,557 | 266,367 | 2,268,819 | 2.3 M to 2.3 M (-1.16 %) | |
| May 09 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.11 | 15,548 | 157,190 | 2,295,376 | 2.3 M to 2.3 M (-0.67 %) | |
| Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 1,120,448 | 0 | 0 | |
| Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 890,476 | 0 | 0 | |
| Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 10.00 | 300,000 | 3,000,000 | 2,310,924 | 2 M to 2.3 M (+14.92 %) |
| Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 2,010,924 | 0 | 2,010,924 | 0 to 2 M |
Page: 1